{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:19:09Z","timestamp":1781223549141,"version":"3.54.1"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>There is a continuously rising incidence of non-alcoholic fatty liver disease (NAFLD) around the world, which parallels the increasing incidence of metabolic diseases. NAFLD is a range of liver conditions that contains simple non-alcoholic fatty liver and advanced non-alcoholic steatohepatitis. In serious cases, NAFLD may develop into cirrhosis or even liver cancer. NAFLD has an intense relationship with metabolic syndrome, type 2 diabetes mellitus. It is known that gut microbiota, and functional molecules such as adenosine monophosphate-activated protein kinase JNK, and peroxisome proliferator-activated receptors (PPARs) in progressing and treating NAFLD. Traditionally, the conventional and effective therapeutic strategy is lifestyle intervention. Nowadays, new medicines targeting specific molecules, such as farnesoid X receptor, PPARs, and GLP-1 receptor, have been discovered and shown beneficial effects on patients with NAFLD. In this article, we focus on the molecular mechanisms and therapeutic approaches to NAFLD.<\/jats:p>","DOI":"10.3389\/fendo.2022.1002916","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T05:25:35Z","timestamp":1669699535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Wensheng","family":"Che","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2013meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"gutjnl","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms, and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/01.mol.0000174153.53683.f2","article-title":"Nonalcoholic fatty liver disease and the metabolic syndrome","volume":"16","author":"Marchesini","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease\u2013an evolving view","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin Liver Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PloS Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12664-020-01020-3","article-title":"Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity","volume":"39","author":"Sinha","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474124.2018.1460202","article-title":"The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"12","author":"Lu","year":"2018","journal-title":"Expert Rev Gastroent"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i16.1901","article-title":"Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view","volume":"26","author":"Chen","year":"2020","journal-title":"World J Gastroentero"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01813","article-title":"Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease","volume":"9","author":"Porras","year":"2018","journal-title":"Front Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900487","article-title":"A network involving gut microbiota, circulating bile acids, and hepatic metabolism genes that protects against non-alcoholic fatty liver disease","volume":"63","author":"Petrov","year":"2019","journal-title":"Mol Nutr Food Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8848","DOI":"10.1038\/s41598-020-65051-8","article-title":"Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Sci Rep-Uk"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5223\/pghn.2013.16.1.22","article-title":"Gut microbiota and clinical disease: Obesity and nonalcoholic fatty liver disease","volume":"16","author":"Park","year":"2013","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109199","article-title":"High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms","volume":"330","author":"Lian","year":"2020","journal-title":"Chem-Biol Interact"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Roy","year":"2013","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06112-w","article-title":"Diet and the human gut microbiome: An international review","volume":"65","author":"Wilson","year":"2020","journal-title":"Digest Dis Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/obr.12122","article-title":"China In the period of transition from scarcity and extensive undernutrition to emerging nutrition-related non-communicable diseases, 1949\u20131992","volume":"15","author":"Du","year":"2014","journal-title":"Obes Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms6040098","article-title":"Gut microbiota in patients with different metabolic statuses: Moscow study","volume":"6","author":"Kashtanova","year":"2018","journal-title":"Microorg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1136\/gutjnl-2018-317609","article-title":"Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: A 6-month randomised controlled-feeding trial","volume":"68","author":"Wan","year":"2019","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/circresaha.117.311401","article-title":"Reactive oxygen species in metabolic and inflammatory signaling","volume":"122","author":"Forrester","year":"2018","journal-title":"Circ Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101284","article-title":"Biochemical basis and metabolic interplay of redox regulation","volume":"26","author":"Zhang","year":"2019","journal-title":"Redox Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0079-5","article-title":"Control and dysregulation of redox signalling in the gastrointestinal tract","volume":"16","author":"Campbell","year":"2019","journal-title":"Nat Rev Gastroentero"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10020174","article-title":"Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy","volume":"10","author":"Arroyave-Ospina","year":"2021","journal-title":"Antioxidants"},{"key":"B33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cell.2020.08.009","article-title":"Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output","volume":"183","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","article-title":"The Nrf2 regulatory network provides an interface between redox and intermediary metabolism","volume":"39","author":"Hayes","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cmet.2018.01.007","article-title":"Digoxin suppresses pyruvate kinase M2-promoted HIF-1\u03b1 transactivation in steatohepatitis","volume":"27","author":"Ouyang","year":"2018","journal-title":"Cell Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroentero"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.035","article-title":"Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin","volume":"48","author":"Bergheim","year":"2008","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: An emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat Rev Gastroentero"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/jci93465","article-title":"Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis","volume":"127","author":"Caussy","year":"2017","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190119113836","article-title":"Genetics of nonalcoholic fatty liver disease: A 2018 update","volume":"24","author":"Valenti","year":"2019","journal-title":"Curr Pharm Design"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment Pharm Therap"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: From new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31032","article-title":"Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the US","volume":"71","author":"Unalp-Arida","year":"2020","journal-title":"Population. Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12656","article-title":"PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease","volume":"30","author":"Shen","year":"2015","journal-title":"J Gastroen Hepatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J Clin Lipidol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.07.036","article-title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial","volume":"63","author":"Scorletti","year":"2015","journal-title":"J Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102247","article-title":"Discovery and targeting of the signaling controls of PNPLA3 to effectively reduce transcription, expression, and function in pre-clinical NAFLD\/NASH settings","volume":"9","author":"Schwartz","year":"2020","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/gad.17420111","article-title":"AMP-activated protein kinase\u2013an energy sensor that regulates all aspects of cell function","volume":"25","author":"Hardie","year":"2011","journal-title":"Gene Dev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32198-1","article-title":"Yeast SNF1 is functionally related to mammalian AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo","volume":"269","author":"Woods","year":"1994","journal-title":"J Biol Chem"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)78143-5","article-title":"Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism","volume":"269","author":"Carling","year":"1994","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat Rev Mol Cell Bio"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m512831200","article-title":"Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle*","volume":"281","author":"Martin","year":"2006","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3109\/10409238.2010.488215","article-title":"AMPK inhibition in health and disease","volume":"45","author":"Viollet","year":"2010","journal-title":"Crit Rev Biochem Mol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2014.08.013","article-title":"Insulin inhibits AMPK activity and phosphorylates AMPK Ser485\/491 through akt in hepatocytes, myotubes and incubated rat skeletal muscle","volume":"562","author":"Valentine","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.11.005","article-title":"Tumor necrosis factor \u03b1-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling","volume":"4","author":"Steinberg","year":"2006","journal-title":"Cell Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.44.27879","article-title":"Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase*","volume":"271","author":"Hawley","year":"1996","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/1475-4924-2-28","article-title":"Complexes between the LKB1 tumor suppressor, STRAD\u03b1\/\u03b2 and MO25\u03b1\/\u03b2 are upstream kinases in the AMP-activated protein kinase cascade","volume":"2","author":"Hawley","year":"2003","journal-title":"J Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1038\/ncomms4017","article-title":"Structural basis of AMPK regulation by small molecule activators","volume":"4","author":"Xiao","year":"2013","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00125-008-1108-7","article-title":"Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients","volume":"51","author":"Boon","year":"2008","journal-title":"Diabetologia"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1530\/jme-13-0277","article-title":"Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease","volume":"52","author":"Nielsen","year":"2014","journal-title":"J Mol Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.01.019","article-title":"Nutrient sensing, metabolism, and cell growth control","volume":"49","author":"Yuan","year":"2013","journal-title":"Mol Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molcel.2017.05.032","article-title":"AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance","volume":"66","author":"Garcia","year":"2017","journal-title":"Mol Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20170774","DOI":"10.1098\/rsif.2017.0774","article-title":"Keeping the home fires burning\u2020: AMP-activated protein kinase","volume":"15","author":"Hardie","year":"2018","journal-title":"J Roy Soc Interface"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00011.2008","article-title":"AMPK in health and disease","volume":"89","author":"Steinberg","year":"2009","journal-title":"Physiol Rev"},{"key":"B66","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tcb.2015.10.013","article-title":"AMPK: An energy-sensing pathway with multiple inputs and outputs","volume":"26","author":"Hardie","year":"2016","journal-title":"Trends Cell Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.11.127","article-title":"Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans","volume":"404","author":"Gauthier","year":"2011","journal-title":"Biochem Bioph Res Co"},{"key":"B68","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1194\/jlr.p022905","article-title":"Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue","volume":"53","author":"Xu","year":"2012","journal-title":"J Lipid Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/jci23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased De novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1989.tb15186.x","article-title":"Purification and characterization of the AMP-activated protein kinase","volume":"186","author":"Carling","year":"1989","journal-title":"Eur J Biochem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(92)90001-c","article-title":"Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase","volume":"1123","author":"Hardie","year":"1992","journal-title":"Biochim Et Biophys Acta Bba - Lipids Lipid Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin\u2013sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","article-title":"AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development","volume":"28","author":"Boudaba","year":"2018","journal-title":"Ebiomedicine"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0542","article-title":"An AMPK\u2013caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0350-5","article-title":"Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer","volume":"559","author":"Wu","year":"2018","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2012.02.003","article-title":"Phosphorylation regulates assembly of the caspase-6 substrate-binding groove","volume":"20","author":"Vel\u00e1zquez-Delgado","year":"2012","journal-title":"Structure"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/550s102a","article-title":"Fighting the fatty liver","volume":"550","author":"Drew","year":"2017","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.039","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis","volume":"54","author":"Ibrahim","year":"2011","journal-title":"J Hepatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m510660200","article-title":"Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis*","volume":"281","author":"Malhi","year":"2006","journal-title":"J Biol Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1053\/j.gastro.2009.06.045","article-title":"C-jun n-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice","volume":"137","author":"Kodama","year":"2009","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-4-28","article-title":"Autophagy protects against palmitate-induced apoptosis in hepatocytes","volume":"4","author":"Cai","year":"2014","journal-title":"Cell Biosci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50135","article-title":"C-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration","volume":"37","author":"Schwabe","year":"2003","journal-title":"Hepatology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041260","article-title":"The role of PPAR and its cross-talk with CAR and LXR in obesity and atherosclerosis","volume":"19","author":"Xu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9735083","article-title":"Loss of hepatocyte-specific PPAR\u03b3 expression ameliorates early events of steatohepatitis in mice fed the methionine and choline-deficient diet","volume":"2020","author":"Cordoba-Chacon","year":"2020","journal-title":"Ppar Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8047627","article-title":"Short-term activation of peroxisome proliferator-activated receptors \u03b1 and \u03b3 induces tissue-specific effects on lipid metabolism and fatty acid composition in Male wistar rats","volume":"2019","author":"Strand","year":"2019","journal-title":"Ppar Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease 1 1 this article is part of a special issue entitled: Xenobiotic nuclear receptors: New tricks for an old dog, edited by dr. wen xie","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim Et Biophys Acta Bba - Gene Regul Mech"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.5.0380","article-title":"Peroxisome proliferator-activated receptors: Nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/234975","article-title":"Role of PPARs in radiation-induced brain injury","volume":"2010","author":"Ramanan","year":"2010","journal-title":"Ppar Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3945\/jn.110.135210","article-title":"PPAR\u03b1 expression protects Male mice from high fat\u2013induced nonalcoholic fatty liver","volume":"141","author":"Abdelmegeed","year":"2011","journal-title":"J Nutr"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118868","article-title":"Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-\u03b1 signaling in obese mice","volume":"266","author":"Diniz","year":"2021","journal-title":"Life Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7242030","article-title":"15-Deoxy-\u0394-12,14-Prostaglandin J2 (15d-PGJ2), an endogenous ligand of PPAR-\u03b3: Function and mechanism","volume":"2019","author":"Li","year":"2019","journal-title":"Ppar Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15028","article-title":"Therapeutic potential of PPAR\u03b3 natural agonists in liver diseases","volume":"24","author":"Wu","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051247","article-title":"Maternal exercise mediates hepatic metabolic programming via activation of AMPK-PGC1\u03b1 axis in the offspring of obese mothers","volume":"10","author":"Kasper","year":"2021","journal-title":"Cells"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3902-y","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao5774","article-title":"Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes","volume":"359","author":"Zhao","year":"2018","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J Hepatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1042\/cs20030326","article-title":"Increase in long-chain polyunsaturated fatty acid n\u20136\/n\u20133 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease","volume":"106","author":"Araya","year":"2004","journal-title":"Clin Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/nu13030739","article-title":"Is the Mediterranean diet the best approach to NAFLD treatment today","volume":"13","author":"Angelico","year":"2021","journal-title":"Nutrients"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-018-0645-9","article-title":"Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota","volume":"12","author":"Han","year":"2018","journal-title":"Front Med-Prc"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788168164","article-title":"The role of the gut microbiota in energy metabolism and metabolic disease","volume":"15","author":"Cani","year":"2009","journal-title":"Curr Pharm Design"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/nu11112837","article-title":"Role of probiotics in non-alcoholic fatty liver disease: Does gut microbiota matter","volume":"11","author":"Xie","year":"2019","journal-title":"Nutrients"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e80169","DOI":"10.1371\/journal.pone.0080169","article-title":"Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice","volume":"9","author":"Ritze","year":"2014","journal-title":"PloS One"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"358","author":"Marchesini","year":"2001","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin e or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bcpt.13535","article-title":"Salsalate reverses metabolic disorders in a mouse model of non-alcoholic fatty liver disease through AMPK activation and caspase-6 activity inhibition","volume":"128","author":"Li","year":"2021","journal-title":"Basic Clin Pharmacol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1039\/d0fo02736g","article-title":"Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD","volume":"12","author":"Li","year":"2021","journal-title":"Food Funct"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-\u03b2 activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504379102","article-title":"Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice","volume":"102","author":"Johansson","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1089\/105072502760143935","article-title":"Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure","volume":"12","author":"Morkin","year":"2002","journal-title":"Thyroid"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0128-3","article-title":"Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPAR\u03b1 agonist with moderate PPAR\u03b3 agonist activity in healthy human subjects","volume":"33","author":"Jani","year":"2013","journal-title":"Clin Drug Invest"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199803263381303","article-title":"Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus","volume":"338","author":"Inzucchi","year":"1998","journal-title":"N Engl J Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: An update","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann Intern Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"J Diabetes Invest"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1172\/jci13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165621","article-title":"Protective effect of metformin against palmitate-induced hepatic cell death","volume":"1866","author":"Geng","year":"2020","journal-title":"Biochim Et Biophys Acta Bba - Mol Basis Dis"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90465-d","article-title":"Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins","volume":"99","author":"Cryer","year":"1990","journal-title":"Gastroenterology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90025-b","article-title":"Gastroduodenal mucosal damage with salsalate versus aspirin: Results of experimental models and endoscopic studies in humans","volume":"20","author":"Scheiman","year":"1990","journal-title":"Semin Arthritis Rheu"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1816","article-title":"Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions","volume":"96","author":"Meex","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B142","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1752-8062.2008.00026.x","article-title":"Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes","volume":"1","author":"Goldfine","year":"2008","journal-title":"Clin Transl Sci"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2823-6","article-title":"Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-\u03b1 and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats","volume":"58","author":"Cheng","year":"2013","journal-title":"Digest Dis Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.m075713","article-title":"Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids","volume":"58","author":"Janssen","year":"2017","journal-title":"J Lipid Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur J Gastroen Hepat"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00352-2","article-title":"Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: Current evidence and perspectives","volume":"8","author":"Vallianou","year":"2019","journal-title":"Curr Obes Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15416","article-title":"Review article: can bugs be drugs? the potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease","volume":"50","author":"Koopman","year":"2019","journal-title":"Aliment Pharm Therap"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.022","article-title":"Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth","volume":"132","author":"Yan","year":"2007","journal-title":"Gastroenterology"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2010.10.008","article-title":"Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin\u2013glucan fiber improves host metabolic alterations induced by high-fat diet in mice","volume":"23","author":"Neyrinck","year":"2012","journal-title":"J Nutr Biochem"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.012","article-title":"Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease","volume":"76","author":"Govaere","year":"2022","journal-title":"J Hepatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium\u2013glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14167","article-title":"Serum coding and noncoding RNAs as biomarkers of NAFLD and fibrosis severity","volume":"39","author":"Mauro","year":"2019","journal-title":"Liver Int"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh1541","article-title":"Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD","volume":"7","author":"Zhang","year":"2021","journal-title":"Sci Adv"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0146","article-title":"A high-fat diet attenuates AMPK \u03b11 in adipocytes to induce exosome shedding and nonalcoholic fatty liver development in vivo","volume":"70","author":"Yan","year":"2021","journal-title":"Diabetes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1002916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T05:25:39Z","timestamp":1669699539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1002916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":155,"alternative-id":["10.3389\/fendo.2022.1002916"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1002916","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1002916"}}